Table 1 Clinical and demographic characteristics of the patients
From: Pirfenidone attenuates lung fibrotic fibroblast responses to transforming growth factor-β1
Characteristics | Control group | PF group | P value |
|---|---|---|---|
Age, y | 64.5 ± 8.1 | 59.1 ± 14.7 | 0.28 |
Sex, (male/female) | 9/3 | 8/4 | 1.00 |
Smoking status (yes/no) | 8/4 | 8/4 | 1.00 |
Pack-years | 712.5 ± 374.4 | 537.5 ± 498.2 | 0.44 |
% FVC | 99.2 ± 4.1 | 85.2 ± 4.8 | 0.04 |
KL-6 (U/mL) | None | 1422.3 ± 595.0 | |
SP-D (ng/mL) | None | 200.7 ± 77.8 | |
Clinical diagnosis | None | IPF(3), NSIP(5), CHP(4)* | |
Histological pattern | None | UIP(6), NSIP(6) |